Literature DB >> 20875068

Pancreatic intraepithelial neoplasia-can we detect early pancreatic cancer?

Beate Haugk1.   

Abstract

Haugk B
(2010) Histopathology 57, 503-514
Pancreatic intraepithelial neoplasia - can we detect early pancreatic cancer? Pancreatic cancer is one of the most lethal cancers, with an incidence equalling mortality. Pancreatic cancer is a heterogeneous group in which pancreatic ductal adenocarcinoma (PDAC) is the most common. It is now established that PDAC develops through stepwise progression from precursor lesions. Detection and treatment of these precursor lesions would allow curative treatment. Three precursor lesions for PDAC have been identified. Two of these - mucinous cystic neoplasms (MCNs) and intraductal papillary mucinous neoplasms (IPMNs) - are rare, radiologically detectable, cystic precursor lesions which can be cured if treated at the preinvasive stage. The third and most common precursor lesion has recently been defined as pancreatic intraepithelial neoplasia (PanIN). PanINs are microscopic lesions with no clinical correlate. They display a spectrum of cyto-architectural changes (PanIN-1, PanIN-2 and PanIN-3) mirrored in an increasing accumulation of molecular genetic changes, with PanIN-3 sharing many of the alterations with PDAC. Great advances in the understanding of pancreatic carcinogenesis have opened avenues for diagnosis and chemoprevention. However, access to the pancreas is limited, molecular tests are at the early stages and too little is known about the natural history of early PanINs to justify resection. Currently, screening focuses upon high-risk individuals only.
© 2010 Blackwell Publishing Limited.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20875068     DOI: 10.1111/j.1365-2559.2010.03610.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  12 in total

1.  Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma.

Authors:  Deyali Chatterjee; Matthew H Katz; Asif Rashid; Jeannelyn S Estrella; Hua Wang; Gauri R Varadhachary; Robert A Wolff; Jeffrey E Lee; Peter W Pisters; James L Abbruzzese; Jason B Fleming; Huamin Wang
Journal:  Histopathology       Date:  2013-09-20       Impact factor: 5.087

2.  TRPC6 channels modulate the response of pancreatic stellate cells to hypoxia.

Authors:  Nikolaj Nielsen; Kateryna Kondratska; Tobias Ruck; Benedikt Hild; Ilya Kovalenko; Sandra Schimmelpfennig; Jana Welzig; Sarah Sargin; Otto Lindemann; Sven Christian; Sven G Meuth; Natalia Prevarskaya; Albrecht Schwab
Journal:  Pflugers Arch       Date:  2017-08-28       Impact factor: 3.657

3.  Novel nano-drug combination therapeutic regimen demonstrates significant efficacy in the transgenic mouse model of pancreatic ductal adenocarcinoma.

Authors:  Arvind Thakkar; Preshita Desai; Sushma Chenreddy; Jalpa Modi; Astrid Thio; Wael Khamas; David Ann; Jeffrey Wang; Sunil Prabhu
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166

4.  Knockdown of angiopoietin-2 suppresses metastasis in human pancreatic carcinoma by reduced matrix metalloproteinase-2.

Authors:  Zi-Xiang Zhang; Jin Zhou; Yi Zhang; Dong-Ming Zhu; De-Chun Li; Hua Zhao
Journal:  Mol Biotechnol       Date:  2013-03       Impact factor: 2.695

5.  The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells.

Authors:  Philip J Vernon; Tara J Loux; Nicole E Schapiro; Rui Kang; Ravi Muthuswamy; Pawel Kalinski; Daolin Tang; Michael T Lotze; Herbert J Zeh
Journal:  J Immunol       Date:  2012-12-26       Impact factor: 5.422

6.  Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Dario Garcia-Carracedo; Andrew T Turk; Stuart A Fine; Nathan Akhavan; Benjamin C Tweel; Ramon Parsons; John A Chabot; John D Allendorf; Jeanine M Genkinger; Helen E Remotti; Gloria H Su
Journal:  Clin Cancer Res       Date:  2013-10-16       Impact factor: 12.531

Review 7.  Pancreatic Cancer and Therapy: Role and Regulation of Cancer Stem Cells.

Authors:  Susmita Barman; Iram Fatima; Amar B Singh; Punita Dhawan
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

Review 8.  Current Status of Immunotherapies for Treating Pancreatic Cancer.

Authors:  Annie A Wu; Elizabeth Jaffee; Valerie Lee
Journal:  Curr Oncol Rep       Date:  2019-05-17       Impact factor: 5.945

9.  Loss of BAP1 Expression Is Very Rare in Pancreatic Ductal Adenocarcinoma.

Authors:  Michael Tayao; Juliana Andrici; Mahtab Farzin; Adele Clarkson; Loretta Sioson; Nicole Watson; Terence C Chua; Tamara Sztynda; Jaswinder S Samra; Anthony J Gill
Journal:  PLoS One       Date:  2016-03-16       Impact factor: 3.240

10.  Characterization of proteins secreted by pancreatic cancer cells with anticancer drug treatment in vitro.

Authors:  Takanobu Takata; Yasuhito Ishigaki; Takeo Shimasaki; Hideyuki Tsuchida; Yoshiharu Motoo; Akio Hayashi; Naohisa Tomosugi
Journal:  Oncol Rep       Date:  2012-09-05       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.